Hot Topic
The Latest
In this month’s “Hot Topic,” Rondell Graham, M.B.B.S., provides an overview of a PRKACA FISH test that assists in differentiating fibrolamellar carcinoma from other subtypes of primary liver cancer.
In this month’s “Hot Topic,” Robin Patel, M.D., will discuss the diagnosis of Helicobacter pylori infection in an era of antimicrobial resistance.
In this month’s “Hot Topic,” Brad Karon, M.D., Ph.D., will discuss recent information on the advantages and disadvantages of using butterfly needles for blood collection.
In this month’s “Hot Topic,” Sounak Gupta, M.B.B.S., Ph.D., discusses selecting tissues and other tissue considerations for molecular testing. He also reviews tissue metrics and requirements, which differ based on test platforms. It is important to keep in mind that the details of tissue metrics change over time as they continue to evolve with technology.
In this month’s “Hot Topic,” Elitza Theel, Ph.D., talks about Mayo Clinic Laboratories’ serologic and molecular testing for the identification of infection with dengue virus. Dengue virus poses a significant public health threat worldwide. Rapid and accurate identification of the infection enables directed monitoring of patients who may be at increased risk of developing hemorrhagic fever of dengue shock syndrome.
In this month’s “Hot Topic,” Julia Lehman, M.D., will explain important changes that are taking place in Mayo Clinic’s Immunodermatology Laboratory to continue offering the highest quality testing for the interpretation of the bullous pemphigoid 180 and 230 and desmoglein 1 and 3 assay results.
In this month’s “Hot Topic,” Paul Jannetto, Ph.D., will highlight Mayo Clinic’s new targeted benzodiazepine assay and discuss the advantages and limitations of various urine-screening assays as well as quantitative confirmatory testing to determine compliance to benzodiazepine therapy.
In this month’s “Hot Topic,” Elitza Theel, Ph.D., will discuss the over utilization of IgM serologic testing for herpes simplex virus and the recommendation by multiple agencies, including the CDC and the Infectious Diseases Society of America, to avoid using this test for clinical decision making purposes. As a result of these recommendations and data generated at Mayo Clinic, Dr. Theel will summarize why HSV IgM testing will no longer be offered through Mayo Clinic Laboratories.